Literature DB >> 28598302

Multi-locus variable-number tandem repeat analysis of Bordetella pertussis isolates circulating in Poland in the period 1959-2013.

Ewa Mosiej1, Katarzyna Krysztopa-Grzybowska1, Maciej Polak1, Marta Prygiel1, Anna Lutyńska1.   

Abstract

PURPOSE: Despite the long history of pertussis vaccination and high vaccination coverage in Poland and many other developed countries, pertussis incidence rates have increased substantially, making whooping cough one of the most prevalent vaccine-preventable diseases. Among the factors potentially involved in pertussis resurgence, the adaptation of the Bordetella pertussis population to country-specific vaccine-induced immunity through selection of non-vaccine-type strains still needs detailed studies.
METHODOLOGY: Multi-locus variable-number tandem repeat analysis (MLVA), also linked to MLST and PFGE profiling, was applied to trace the genetic changes in the B. pertussis population circulating in Poland in the period 1959-2013 versus country-specific vaccine strains.
RESULTS: Generally, among 174 B. pertussis isolates, 31 MLVA types were detected, of which 11 were not described previously. The predominant MLVA types of recent isolates in Poland were different from those of the typical isolates circulating in other European countries. The MT27 type, currently predominant in Europe, was rarely seen and detected in only five isolates among all studied. The features of the vaccine strains used for production of the pertussis component of a national whole-cell diphtheria-tetanus-pertussis (DTP) vaccine, as studied by MLVA and MLST tools, were found to not match those observed in the currently circulating B. pertussis isolates in Poland.
CONCLUSIONS: Differences traced by MLVA in relation to the MLST and PFGE profiling confirmed that the B. pertussis strain types currently observed elsewhere in Europe, even if appearing in Poland, were not able to successfully disseminate within a human population in Poland that has been vaccinated with a whole-cell pertussis vaccine not used in other countries.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28598302     DOI: 10.1099/jmm.0.000408

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  5 in total

1.  Bordetella pertussis population changes under whole-cell and acellular pertussis vaccines-induced immunity selection pressure in Poland.

Authors:  Maciej Polak; Ewa Mosiej; Marta Prygiel; Aleksandra A Zasada
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-09-14       Impact factor: 5.103

2.  Population dynamics and antigenic drift of Bordetella pertussis following whole cell vaccine replacement, Barcelona, Spain, 1986-2015.

Authors:  Alba Mir-Cros; Albert Moreno-Mingorance; M Teresa Martín-Gómez; Gema Codina; Thais Cornejo-Sánchez; Mireia Rajadell; Diego Van Esso; Carlos Rodrigo; Magda Campins; Mireia Jané; Tomàs Pumarola; Anna Fàbrega; Juan José González-López
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163

3.  Molecular epidemiology of Bordetella pertussis in Greece, 2010-2015.

Authors:  Evangelia Petridou; Christel Barker Jensen; Athanasios Arvanitidis; Maria Giannaki-Psinaki; Athanasios Michos; Karen Angeliki Krogfelt; Randi Føns Petersen
Journal:  J Med Microbiol       Date:  2018-02-02       Impact factor: 2.472

4.  Genomic epidemiology of Iranian Bordetella pertussis: 50 years after the implementation of whole cell vaccine.

Authors:  Azadeh Safarchi; Sophie Octavia; Vajihe Sadat Nikbin; Masoumeh Nakhost Lotfi; Seyed Mohsen Zahraei; Chin Yen Tay; Binit Lamichhane; Fereshteh Shahcheraghi; Ruiting Lan
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163

5.  Effectiveness of experimental and commercial pertussis vaccines in the elimination of Bordetella pertussis isolates with different genetic profiles in murine model.

Authors:  Marta Prygiel; Ewa Mosiej; Karol Wdowiak; Paulina Górska; Maciej Polak; Klaudia Lis; Katarzyna Krysztopa-Grzybowska; Aleksandra Anna Zasada
Journal:  Med Microbiol Immunol       Date:  2021-08-02       Impact factor: 3.402

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.